2016
Group Leader
José Yélamos López
The aim of this group is to investigate the role of poly(ADP-ribosyl)ation of nuclear proteins, catalysed by PARP family members (specially PARP-1 and PARP-2), as a critical signaling pathway at nuclear level, in both innate and acquire immune response. The results from this study could allow identifying new therapeutic target in different pathophysiological conditions associated with the immune system.
more info
Main Publications
• Martínez-Bosch N, Fernández-Zapico ME, Navarro P, Yélamos J. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases. Am J Pathol 2016; 186(2): 234-241. IF 4.206. Q1.
• Yélamos J, Galindo M, Navarro J, Albanell J, Rovira A, Rojo F, Oliver J. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. OncoImmunology 2016; 5(1): e1065370. IF 7.644. Q1.
Ongoing Research Projects
• Estudio de la interacción entre rutas de señalización mediadas por Poli-ADP-ribosilación y fosforilación en la respuesta al daño en el DNA y sus implicaciones en cáncer
− Ministerio de Economía y Competitividad (SAF2014-53467-R)
− From 2015 to 2017
− Principal investigator: Yélamos López, José
• Exploring synthetic lethal interactions between PARP and the DNA damage response in cancer treatment
− Fundació La Marató de TV3 (20134130)
− From 2014 to 2017
− Principal investigator: Yélamos López, José
Group’s Recognitions
• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca en Diferenciació i Fisiopatologia Limfocitària (2014-2017)
− Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 184)
− Principal investigator: Yélamos López, José
Theses
• Navarro J. Understanding functional interplay between PARP-1 and PARP-2 in T cell development and function. Pompeu Fabra University
− Directors: Yélamos López, José; Martín-Caballero, J
− Date of defense: 15/12/2016.
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es